SCHEMBL21033487

SCHEMBL21033487

CCOC(=O)c1cn2cc(-c3noc(C4CC4)n3)ccc2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.49
NPC1 O15118 4/20 0.49
HTT P42858 3/20 0.49
LMNA P02545 2/20 0.49
KDM4E B2RXH2 2/20 0.49
POLB P06746 1/20 0.49
CPT1A P50416 1/20 0.49
TUBB4A P04350 3/20 0.46
TUBB P07437 3/20 0.46
TUBA3C P0DPH7 3/20 0.46
TUBA1B P68363 3/20 0.46
TUBA4A P68366 3/20 0.46
TUBB4B P68371 3/20 0.46
TUBB3 Q13509 3/20 0.46
TUBB2A Q13885 3/20 0.46
TUBB8 Q3ZCM7 3/20 0.46
TUBA3E Q6PEY2 3/20 0.46
TUBA1A Q71U36 3/20 0.46
TUBA1C Q9BQE3 3/20 0.46
TUBB6 Q9BUF5 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21001692 0.85 KDM4E (0.54) RAB9ANPC1HTTLMNAKDM4E
SCHEMBL21033299 0.84 CA12 (0.47) RAB9ANPC1HTTLMNATUBB4A
SCHEMBL21033486 0.82 KDM4E (0.50) RAB9ANPC1HTTLMNAKDM4E
SCHEMBL21033488 0.82 HDAC4 (0.53) KDM4EPOLB
SCHEMBL21033484 0.82 KDM4E (0.50) RAB9ANPC1HTTKDM4EPOLB
SCHEMBL21355432 0.78 KDM4E (0.59) RAB9ANPC1KDM4EPOLBGAA
SCHEMBL21033470 0.78 KDM4E (0.53) RAB9ANPC1KDM4EPOLBGAA
SCHEMBL4083192 0.74 KDM4E (0.60) RAB9ANPC1KDM4EPOLBGAA
SCHEMBL3767499 0.74 KDM4E (0.54) RAB9ANPC1KDM4EPOLBGAA
SCHEMBL21355999 0.74 KDM4E (0.56) RAB9ANPC1KDM4EPOLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210371431-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS JUBILANT EPISCRIBE LLC 2021-12-02 US disclosed
WO-2019102494-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2019-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210371431-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 RAB9A 462/4885NPC1 3585/4885HTT 1227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.